therapy for anemic myelodyspastic patients
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study / Sekeres, M.A., Santini, V., Díez-Campelo, M., Komrokji, R.S., Fenaux, P., Savona, M.R., Madanat, Y.F., Valcárcel-Ferreiras, D., Oliva, E.N., Regnault, A., Creel, K., Sengupta, N., Dougherty, S., Shah, S., Sun, L., Wan, Y., Navada, S., Zeidan, A.M., Platzbecker, U.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - ELETTRONICO. - (2024), pp. 1-6. [10.1080/10428194.2024.2426057]
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study
Santini, ValeriaMembro del Collaboration Group
;
2024
Abstract
therapy for anemic myelodyspastic patients
| File | Dimensione | Formato | |
|---|---|---|---|
|
Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for or relapsed refract.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.16 MB
Formato
Adobe PDF
|
1.16 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
